RupeestopAbout UsNewsletter

Compiled by Rupeestop LLP, SEBI RIA INA000022701. NAV as on 19 Aug 2026. Factsheet Jun 2026. About · Disclosures

Mirae Asset Healthcare Fund - Direct Plan - Growth

Mirae Asset Management
Sectoral Pharma and HealthcareDirectGrowthVery high risk
NAV

₹51.274

As on 19 Aug 2026

Vs category

PeriodThis fundCategoryRank
1 year+18.16%
3 year+22.72%
5 year+16.19%
Sharpe
1.13
Std dev
16.89%
Beta
0.98

All Sectoral Pharma and Healthcare funds · Mirae Asset Management

Returns

From NAVs through 19 Aug 2026

1Y
+18.16%
Total
3Y
+22.72%
p.a.
5Y
+16.19%
p.a.
SI
+17.17%
p.a.

Calendar years

-10.47%
2022
+36.06%
2023
+41.20%
2024
-1.99%
2025
+19.62%
2026 YTD

Rolling 1-year · 51 overlapping windows

-9.79%avg +17.09%+58.11%

Fund facts

Fund details from the Jun 2026 factsheet

Fund size
₹3,090.51 Cr
Expense ratio
0.44%
Exit load
None
Lock-in
None
BenchmarkBSE Healthcare TRI
Launched01 Jun 2018
Risk levelVery high
StructureOpen Ended
ISININF769K01ED6

Where the money is invested

Split by asset type.

By asset type

Equity99.36%
Cash0.64%
Other0.01%

What the fund holds

35 holdings · portfolio as on 30 May 2026

  • Sun Pharmaceuticals Industries Ltd
    Healthcare
    11.13%
  • Divi's Laboratories Ltd
    Healthcare
    8.03%
  • J.B. Chemicals & Pharmaceuticals Ltd
    Healthcare
    6.45%
  • Glenmark Pharmaceuticals Ltd
    Healthcare
    6.4%
  • Apollo Hospitals Enterprise Ltd
    Healthcare
    6.04%
  • Laurus Labs Ltd
    Healthcare
    4.35%
  • Lupin Ltd
    Healthcare
    4.28%
  • Dr Reddy's Laboratories Ltd
    Healthcare
    4.27%
  • Aurobindo Pharma Ltd
    Healthcare
    4.12%
  • Fortis Healthcare Ltd
    Healthcare
    3.88%

Concentration

Top 5 weight
38.05%
Top 10 weight
58.95%
Avg turnover
43.33%

Risk and quality measures

How steady the returns have been.

Return quality

Sharpe
1.13
Better than category avg 0.98
Sortino
1.7
Return per unit of downside risk
Alpha
1.25
Return above the benchmark
Information ratio
0.05
Consistency of outperformance

Risk

Std deviation
16.89%
How much returns swing
Beta
0.98
Below category avg 0.95
R-squared
96.3%
How closely it tracks the benchmark

Who manages this fund

2 fund managers

  • VK
    Vrijesh Kasera
    7.7 years in the industry
    Runs 4 schemes
  • TM
    Tanmay Mehta
    0.9 years in the industry
    Runs 1 scheme

Other versions

  • regularGrowth
    Mirae Asset Healthcare Fund - Regular Plan - Growth
    NAV ₹39.22
  • directIDCW
    Mirae Asset Healthcare Fund - Direct Plan - IDCW Payout
    NAV ₹28.84
  • regularIDCW
    Mirae Asset Healthcare Fund - Regular Plan - IDCW Payout
    NAV ₹25.18

FAQ

What is Mirae Asset Healthcare Fund - Direct Plan - Growth NAV today?

The latest NAV of Mirae Asset Healthcare Fund - Direct Plan - Growth is ₹51.274 as on 19 Aug 2026.

How has Mirae Asset Healthcare Fund - Direct Plan - Growth performed vs its category?

1-year return +18.16%. Past performance does not guarantee future returns.

What are the returns of Mirae Asset Healthcare Fund - Direct Plan - Growth?

Trailing returns from published NAVs: 1 year +18.16%, 3 year +22.72% a year, 5 year +16.19% a year, since our first NAV +17.17% a year. Past performance does not guarantee future returns.

How would a SIP in Mirae Asset Healthcare Fund - Direct Plan - Growth have been illustrated?

The SIP illustration on this page uses ₹5,000 a month for 10 years at this fund's 3-year annualised return of +22.72%. It is not a forecast.

What is the expense ratio and fund size of Mirae Asset Healthcare Fund - Direct Plan - Growth?

For Mirae Asset Healthcare Fund - Direct Plan - Growth, the expense ratio is 0.44% and fund size (AUM) is ₹3,090.51 Cr.

What is the ISIN of Mirae Asset Healthcare Fund - Direct Plan - Growth?

The ISIN for Mirae Asset Healthcare Fund - Direct Plan - Growth is INF769K01ED6.

Mutual fund investments are subject to market risks. Read all scheme related documents carefully before investing. Past performance does not guarantee future returns and is not an indicator of future results.

Figures on this page come from published NAVs and the scheme's monthly factsheet. They are for information only and are not investment advice or a recommendation to buy or sell any scheme.